Physician profile
Matthew T Brink
NPI 1104209931
$4,047.89
in general payments reported to CMS, 2019-2025
26 companies · $488 in 2025
The $488 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,033 · 2020: $693 · 2021: $336 · 2022: $343 · 2023: $607 · 2024: $547 · 2025: $488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,643.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,642.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,006.93 | 2019-2025 | Repatha, Otezla, Prolia |
| Novo Nordisk INC | $530.14 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $511.74 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $353.74 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $186.45 | 2019-2024 | Jardiance, Spiriva Respimat, Tradjenta |
| Lilly USA, LLC | $164.88 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Abbvie INC. | $147.11 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $143.97 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $128.16 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $124.07 | 2019-2024 | Gardasil 9, Vaxelis, Vaxneuvance |
| Sanofi-Aventis U.S. LLC | $119.99 | 2020-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $108.22 | 2023-2025 | |
| Astellas Pharma US INC | $97.72 | 2019-2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $92.91 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $87.83 | 2019-2023 | Eliquis |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $56.19 | 2020-2024 | Freestyle Libre 3 |
| Arbor Pharmaceuticals, INC. | $31.99 | 2019-2020 | |
| Welch Allyn | $24.38 | 2021 | |
| Daiichi Sankyo INC. | $21.64 | 2020 | |
| Axsome Therapeutics, INC. | $18.47 | 2025 | Auvelity |
| Recor Medical INC | $17.79 | 2024 | Paradise Renal Denervation System |
| Amarin Pharma, INC. | $16.77 | 2019 | |
| Eisai INC. | $16.77 | 2020 | |
| Philips North America LLC | $15.42 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $12.49 | 2020 | |
| Allergan, INC. | $12.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Brink listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.